Results 51 to 60 of about 2,602 (175)

Retreatment of Direct Acting Agents (DAAs) After Initial DAA Failure in Hepatitis C Patients

Hepatology Research, EarlyView.
ABSTRACT Background and Aims Glecaprevir/pibrentasvir (GLE/PIB) and sofosbuvir/ledipasvir (SOF/LDV) are widely used as first‐line direct‐acting antiviral (DAA) regimens for chronic hepatitis C, achieving high virus eradication rates. However, a small proportion of patients experience treatment failure, and the optimal retreatment strategies for such ...
Nobuharu Tamaki, Masayuki Kurosaki, Hironori Ochi, Hideki Fujii, Yuichiro Suzuki, Takuya Sho, Hayato Hikita, Hiroyuki Marusawa, Yasuhiro Asahina, Namiki Izumi, Tatsuya Kanto   +10 more
wiley   +1 more source

Efficacy and safety of daclatasvir and asunaprevir for hepatitis C virus genotype 1b infection [PDF]

Clinical and Molecular Hepatology, 2016
Background/Aims: The treatment strategy for hepatitis C virus (HCV) has been changing rapidly since the introduction of direct-acting antivirals such as daclatasvir (DCV) and asunaprevir (ASV).
Hee Chul Nam, Hae Lim Lee, Hyun Yang, Myeong Jun Song   +3 more
doaj   +1 more source

Impact of M2BPGi on the Hepatocarcinogenesis after the Combination Therapy with Daclatasvir and Asunaprevir for Hepatitis C

Biomedicines, 2021
The clinical significance of mac-2 binding protein glycosylation isomer (M2BPGi) levels based on virological responses due to antiviral therapy has not been fully evaluated.
Satoshi Takakusagi, Ken Sato, Kyoko Marubashi, Kazuko Kizawa, Takashi Kosone, Satoru Kakizaki, Hitoshi Takagi, Toshio Uraoka   +7 more
doaj   +1 more source

A Hepatitis C Virus-Associated Cirrhotic Patient Developing Interstitial Pneumonia during the Course of Antiviral Therapy with Ombitasvir/Paritaprevir/Ritonavir

Case Reports in Gastroenterology, 2017
Oral direct-acting antivirals (DAAs) are the main therapy for hepatitis C virus (HCV)-associated liver disease in Japan. Daclatasvir/asunaprevir is the first agent and sofosbuvir/ledipasvir is the secondary agent for HCV genotype 1b.
Kazuo Tarao, Kouzo Yamada
doaj   +1 more source

EIF1AX Nucleolar Condensates Enhance Susceptibilities for the Management of Endometrial Cancer

Advanced Science, Volume 13, Issue 12, 27 February 2026.
This schematic illustrates the mechanism of a senolytic strategy in endometrial cancer. EIF1AX facilitates the incorporation of DDX21 into nucleolar condensates, an event that suppresses rDNA transcription and induces cellular senescence. The compound 2,5‐MeC exploits this pathway by promoting EIF1AX nucleolar translocation and condensate formation ...
Chengyu Lv, Zihang Lin, Jiandong Sun, Yuhong Ye, Qibin Wu, Liangzhi Cai, Dabin Liu, Pengming Sun, Shie Wang   +8 more
wiley   +1 more source

Successful Treatment for Chronic Hepatitis C-Autoimmune Hepatitis Overlap Syndrome due to Daclatasvir and Asunaprevir

Case Reports in Gastroenterology, 2017
Persistent hepatitis C virus (HCV) infection may induce autoimmune diseases and chronic hepatitis C is sometimes accompanied by autoimmune hepatitis (AIH).
Ayumi Sugiura, Shuichi Wada, Hiromitsu Mori, Takefumi Kimura, Yoshiaki Matsuda, Naoki Tanaka, Eiji Tanaka, Kendo Kiyosawa   +7 more
doaj   +1 more source

Complex Pattern of Resistance-Associated Substitutions of Hepatitis C Virus after Daclatasvir/Asunaprevir Treatment Failure. [PDF]

PLoS ONE, 2016
We aimed to clarify the characteristics of resistance-associated substitutions (RASs) after treatment failure with NS5A inhibitor, daclatasvir (DCV) in combination with NS3/4A inhibitor, asunaprevir (ASV), in patients with chronic hepatitis C virus ...
Jun Itakura, Masayuki Kurosaki, Chitomi Hasebe, Yukio Osaki, Kouji Joko, Hitoshi Yagisawa, Shinya Sakita, Hiroaki Okushin, Takashi Satou, Hiroyuki Hisai, Takehiko Abe, Keiji Tsuji, Takashi Tamada, Haruhiko Kobashi, Akeri Mitsuda, Yasushi Ide, Chikara Ogawa, Syotaro Tsuruta, Kouichi Takaguchi, Miyako Murakawa, Yasuhiro Asahina, Nobuyuki Enomoto, Namiki Izumi   +22 more
doaj   +1 more source

Pre‐Treatment Liver Stiffness Is a Stronger Predictor of Hepatocellular Carcinoma Development Than Post‐Treatment Liver Stiffness After Hepatitis C Virus Eradication

Hepatology Research, Volume 56, Issue 2, Page 161-171, February 2026.
Higher pre‐treatment liver stiffness measurement (LSM) values, rather than post‐treatment values, independently predicts hepatocellular carcinoma after hepatitis C virus eradication, underscoring the need for continued surveillance in patients with elevated baseline LSM.
Takuma Nakatsuka, Ryo Nakagomi, Keisuke Mabuchi, Yuki Matsushita, Tomoharu Yamada, Kazuya Okushin, Tatsuya Minami, Masaya Sato, Koji Uchino, Yotaro Kudo, Mitsuhiro Fujishiro, Kazuhiko Koike, Ryosuke Tateishi   +12 more
wiley   +1 more source

Cost-effectiveness of daclatasvir plus asunaprevir for chronic hepatitis C genotype 1b treatment-naïve patients in China. [PDF]

PLoS ONE, 2018
BACKGROUND:Hepatitis C is the second fastest growing infectious disease in China. The standard-of-care for chronic hepatitis C in China is Pegylated interferon plus ribavirin (PR), which is associated with tolerability and efficacy issues. An interferon-
Yun Lu, Xiuze Jin, Cheng-A-Xin Duan, Feng Chang   +3 more
doaj   +1 more source

Frequencies of circulating MAIT cells are diminished in chronic hCV, HIV and HCV/ HIV Co-Infection and do not recover during therapy [PDF]

, 2016
Objective Mucosal-associated invariant T (MAIT) cells comprise a subpopulation of T cells that can be activated by bacterial products and cytokines to produce IFN-γ.
Beudeker, B.J.B. (Boris J. B.), Boonstra, P.A. (André), Claassen, M.A.A. (Mark), Groothuismink, Z.M.A. (Zwier), Hullegie, S.J. (Sebastiaan), Knegt, R.J. (Robert) de, Kreefft, K. (Kim), Oord, G.W. (Gertine) van, Rijnders, B.J.A. (Bart), Spaan, M. (Michelle), Van Tilborg, M. (Marjolein)   +10 more
core   +1 more source